ALSO READGranules India's subsidiary enters into product in-licensing agreement Granules India fixes record date for 1st interim dividend Granules India Q1 net up 37 pc at Rs 39 cr Granules India standalone net profit rises 17.27% in the June 2016 quarter Granules India consolidated net profit rises 36.51% in the June 2016 quarter
From USFDAGranules India announced that US FDA has approved Abbreviated New Drug Applications (ANDA) for Ibuprofen Tablets USP, 200 mg (OTC) filed by Granules India. The approved Abbreviated New Drug Applications is the bioequivalent to the reference listed drug product (RLD), Motrin IB Tablets, 200 mg, of Johnson & Johnson Consumer, Inc.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)